Advertisement

Topics

ASIA PACIFIC INTRAUTERINE CONTRACEPTIVE DEVICE MARKET FORECAST 20172025 [Report Updated: 16102017] Prices from USD $1250

18:55 EST 14 Nov 2017 | BioPortfolio Reports

KEY FINDINGS

The AsiaPacific intrauterine contraceptive device market was valued at $1274 million in 2016. The market is anticipated to rise with a CAGR of 4.20%, generating $1832 million over the forecast period of 20172025.

MARKET INSIGHTS

The market is segmented by type and by product. Presently, the copper IUCD market holds a major share of the market. The market is fast gaining momentum in the AsiaPacific region for applications like birth control or for preventing endometrial malignancy issues like squamous or adenosquamous cell carcinoma. China is expected to be the biggest contributor to this market. The Chinese market is chiefly being driven by the various awareness initiatives undertaken by the schools and other educational institutions regarding the benefits of IUD to avoid unwanted teen pregnancy.

COMPETITIVE INSIGHTS

Allergan Plc, Zhejiang Daji Medical Instruments Co Ltd, HLL Lifecare Limited, Bayers Ag, Ocon Medical Ltd, Krishco Medical Products Pvt.Ltd, Okamoto Industries, Pfizer, Medisafe Distribution Inc, Teva Pharmaceutical Industries Limited, and Meril Life Sciences Private Limited are some of the noted companies in the region.

Original Article: ASIA PACIFIC INTRAUTERINE CONTRACEPTIVE DEVICE MARKET FORECAST 20172025 [Report Updated: 16102017] Prices from USD $1250

NEXT ARTICLE

More From BioPortfolio on "ASIA PACIFIC INTRAUTERINE CONTRACEPTIVE DEVICE MARKET FORECAST 20172025 [Report Updated: 16102017] Prices from USD $1250"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...